EGFR and central nervous system cancer: At the same time, the combination of circRNAs with epidermal growth factor receptor (EGFR) [19] or histone deacetylase (HDAC) inhibitors [20] has shown significant potential in restoring drug sensitivity in resistant glioma cells.